Please ensure Javascript is enabled for purposes of website accessibility

Are COVID-19 Boosters Really Needed?

By Keith Speights and Brian Orelli, PhD – Aug 27, 2021 at 6:20AM

Key Points

  • Booster doses for mRNA vaccines are on the way.
  • Waning protection provided by the vaccines factored into the federal government's decision to move forward with booster doses.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The government probably prefers to be safe rather than sorry.

The federal government has cleared the way for booster doses for Americans who have received messenger RNA vaccines. These third doses should be received eight months after the second dose was administered. In this Motley Fool Live video recorded on Aug. 18, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not booster shots are really necessary.

10 stocks we like better than Pfizer
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 9, 2021

 

Keith Speights: Then we have The Fourth Horseman says that, "This is some great lobbying by Pfizer (PFE -0.16%) et al. I wouldn't mind getting a booster shot at all. But can one really say based on the data we have that it's necessary? I'm just sad I don't own this stock."

Brian, what do you think? Based on the data, are the booster shots necessary?

Brian Orelli: I think that the data that says that they are becoming necessary is that people that are vaccinated are getting sick. If most of the cases are mild cases that go away on their own, then you can maybe argue that we don't need to booster, although there's, of course, this whole long COVID thing where people who have COVID end up with symptoms that last beyond the initial infection and so I think that's going to be the case.

They promised that it's going to take a long time to actually figure out whether we need them, and so I think governments are going to make decisions fairly quickly, maybe even before we necessarily know if we need them because they'd rather be safe than sorry. So I think the vaccines are safe enough, that justifies maybe going in a little bit earlier than we would really need to.

I don't think that many people are getting hospitalized that are vaccinated, but there are some people. The other problem is probably only a subset of people actually need to get the booster, but unless you go test everybody's antibody levels, you're not going to know whether people actually need the boosters and that's not practical.

Basically, you're just going to give the booster shots to everybody and then some people will have not actually needed them and some people will, but it's easier to do it that way than to try to test everybody's antibody levels and only give it to the people who have low antibody levels.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.49 (-0.16%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.